BS_8ZS9F31R
high-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- high-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- high-grade glioma
- overall_survival_months
- 32.55584756898817
- age_years
- 10.452
- sex
- Female
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_3BDAG9YN | medulloblastoma | — | 0.935 |
| 2 | SRR6013564 | — | cohortSQ2 | 0.918 |
| 3 | BS_M84H3KXA | Med | Medulloblastoma | 0.884 |
| 4 | MDT-AP-0322 | Med | Medulloblastoma | 0.880 |
| 5 | MDT-AP-0359 | Med | Medulloblastoma | 0.870 |
| 6 | TCGA-E9-A1RB-01A-11R-A157-07 | — | C | 0.869 |
| 7 | MDT-AP-3322 | Med | Medulloblastoma | 0.858 |
| 8 | MNG1011 | — | — | 0.855 |
| 9 | MNG1063 | — | — | 0.855 |
| 10 | SRR4195653 | — | — | 0.853 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.765 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.726 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.669 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.608 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.583 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.466 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.414 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.403 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.295 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.245 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.216 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.214 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.196 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.179 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.177 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.170 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.158 | Inavolisib | — uncovered |
| PEROXISOME | 0.146 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.130 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.099 | Inavolisib | — uncovered |